A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS AstraZeneca Tops Foreign Pharma Ranking in 2021, Pfizer Sales Undisclosed: Jiho
May 27, 2022
-
REGULATORY Japan Approves Additional Indications, Dosages for Rinvoq, Adcetris, Rozex, and More
May 27, 2022
-
BUSINESS Top 4 Wholesalers Log 62% Rise in Operating Profit in FY2021 on Rebound in Doctor Visits
May 27, 2022
-
BUSINESS Sandoz Japan on Hunt for Biosimilar In-Licensing, Sales Tie-Ups after Avastin Deal
May 26, 2022
-
BUSINESS Japan Pharma Market Up 3.3% in FY2021, Opdivo Rises to No.1: IQVIA
May 26, 2022
-
REGULATORY MOF Panel Nudges Full Annual Drug Re-Pricing, Phase-Out for 2% Buffer Zone
May 26, 2022
-
BUSINESS Vabysmo, Ondexxya, Ozempic 2 mg Pen Now Available in Japan
May 26, 2022
-
BUSINESS Novavax Vaccine Officially Added to Japan’s Free COVID-19 Inoculation Program
May 26, 2022
-
BUSINESS BMS CEO Sees Faster Drug Development as Industry Imperative after COVID Vaccine Feat
May 25, 2022
-
BUSINESS US Business Made or Broke FY2021 Earnings of Big 3 Generic Makers; Nichi-Iko, Sawai Suffer Losses
May 24, 2022
-
REGULATORY 2 mg Pen of Supply-Crippled Ozempic, 3rd Avastin Biosimilar Get Japan Listing
May 24, 2022
-
REGULATORY Japan’s Emergency Approval System Comes into Force, Nod Based on Presumed Efficacy
May 23, 2022
-
REGULATORY MOF Budget Examiner Presses for “Full” Annual Re-Pricing, Stepwise Cut in 2% Buffer Zone If No Reasonable Basis Given
May 20, 2022
-
REGULATORY Chuikyo OKs Listing of 14 Drugs on May 25, Biggest Peak Sales Forecast for Vabysmo
May 19, 2022
-
REGULATORY 4 Drugs Face Zero Premium Rule for Low Cost Disclosures: May Price Listing
May 19, 2022
-
BUSINESS Argenx CEO Sees Big Potential for Vyvgart with 100-Plus Diseases Driven by IgGs; Analysts Peg Peak Sales at US$5-10 Billion
May 18, 2022
-
BUSINESS AstraZeneca Ranks Third in Japan Sales Ranking with 12.1% Growth, Good Start in Q1 Too
May 18, 2022
-
ORGANIZATION PhRMA Urges Japan to Exclude Patented Products from Off-Year Re-Pricing in 2023, Create Innovation Ecosystem
May 17, 2022
-
BUSINESS Nichi-Iko Seeks Debt Workout amid US Pipeline Delays and Quality Woes, but President to Stay
May 16, 2022
-
BUSINESS Sumitomo Pharma Likely to Miss 5-Year Biz Targets as COVID Hobbles US Launches
May 16, 2022
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…